Anchen Sues Labopharm In Bid To Sell Generic Ryzolt

Law360, New York (September 30, 2010, 1:25 PM EDT) -- Anchen Pharmaceuticals Inc. has launched a declaratory judgment suit asserting that its plans to market a generic version of pain reliever Ryzolt does not violate a patent held by Canadian drugmaker Labopharm Inc.

Irvine, Calif.-based Anchen filed a complaint Monday in the U.S. District Court for the District of Columbia, claiming that a Labopharm patent that covers Ryzolt is invalid and not infringed.

The suit — filed on behalf of Anchen by Michael Gatje, Donald Mizerk and John Sholar of Husch Blackwell LLP — also targets...
To view the full article, register now.